Subspecialty	Medical Oncology
Clinical Interests	Breast Cancer
	Colon Cancer
	Lymphoma
	Melanoma
	Gastrointestinal Cancer
	Hematology
	Neoplastic Disease
	Prostate
Gender	Male
E-mail	samuel.waxman@mssm.edu
Education and Training	MD, S.U.N.Y., Health Science Center
	Residency, Internal Medicine, Mount Sinai Hospital
	Residency, Internal Medicine, Mount Sinai Hospital
	Fellowship, Hematology, Mount Sinai Hospital

A valued member of Mount Sinai's faculty for over 30 years, Samuel Waxman is the Zena and Michael A. Wiener Professor of Medicine (Cancer). Dr. Waxman currently holds a variety of positions, including Professor Consultant, Shanghai Second Medical University, Head, Rochelle Belfer Chemotherapy Foundation Laboratory in the Division of Medical Oncology at The Mount Sinai Medical Center, and Medical Director, Samuel Waxman Cancer Research Foundation.

Education and Training	MD, S.U.N.Y., Health Science Center
	Residency, Internal Medicine, Mount Sinai Hospital
	Residency, Internal Medicine, Mount Sinai Hospital
	Fellowship, Hematology, Mount Sinai Hospital

Subspecialty	Medical Oncology
Clinical Interests	Breast Cancer
	Colon Cancer
	Lymphoma
	Melanoma
	Gastrointestinal Cancer
	Hematology
	Neoplastic Disease
	Prostate

Ferrari AC, Waxman S. Differentiation Agents in Cancer Therapy. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer Chemotherapy and Biological Response Modifiers Annual 15. B.V., Elsevier Science; 1994.

Jing Y, Zhang J, Bleiweiss IB, Waxman S, Zelent A, Mira-Y-Lopez R . Defective expression of cellular retinol binding protein type I and retinoic acid receptors a2, b2, and g2 in human breast cancer cells. FASEB J 1996; 10: 1064-1070.

Jing Y, Waxman S, Mira-Y-Lopez R . The cellular retinoic acid binding protein II is a positive regulator of retinoic acid signaling in breast cancer cells. Cancer Res 1997; 57: 1668-1672.

Dai J, Weinberg R, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277.

Waxman S. Differentiation therapy in acute myelogenous leukemia (non-APL). Leukemia 2000; 14: 491-496.

Huang Y, Waxman S. Regrowth of 5-fluorouracil treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin and phenylbutyrate. Cancer Research 2000; 60: 3200-3206.